Company
Headquarters: Tonghua, China
Employees: 951
CEO: Mr. Hong Zhang
HK$761.9 Million
HKD as of July 1, 2024
US$97.5 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, bulk drugs, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Tonghua, China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Jilin Province Huinan Changlong Bio-pharmacy Company Ltd has the following listings and related stock indices.
Stock: HKEX: 8049 wb_incandescent